drugset / Trial / NCT04161001

Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451

NCT04161001

Phase 3 Unknown 237 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupDouble-blindTreatment

Summary

* the change of sitSBP based on baseline between Treatment arm and control 1 arm \[ Time Frame: 8 weeks \] * the change of LDL-C based on baseline between Treatment arm and control2 arm \[ Time Frame: 8 weeks \]

Timeline

Start
2019-11-20
Primary completion
2021-11-20
Completion
2022-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 10 mg
Subject Ezetimibe Unknown 10 mg
Subject Rosuvastatin Small molecule 20 mg
Comparator Olmesartan Other / unclassified 40 mg

Indications

No indication recorded.